Quantbot Technologies LP Invests $1.31 Million in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Quantbot Technologies LP has acquired a new stake in ANI Pharmaceuticals, purchasing 19,585 shares valued at approximately $1.31 million. This investment represents a small ownership of 0.09% in the company.
• Insider trading activity includes significant sales by COO Muthusamy Shanmugam and CEO Nikhil Lalwani, with the two selling a combined total of over $9.5 million in stock recently.
• ANI Pharmaceuticals reported strong quarterly earnings with an EPS of $1.80, surpassing analysts’ expectations, and revenue growth of 53.2% year-over-year.

Quantbot Technologies LP purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,585 shares of the specialty pharmaceutical company's stock, valued at approximately $1,311,000. Quantbot Technologies LP owned approximately 0.09% of ANI Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. National Bank of Canada FI bought a new position in shares of ANI Pharmaceuticals during the first quarter worth $79,000. GAMMA Investing LLC lifted its position in ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after acquiring an additional 881 shares in the last quarter. Rafferty Asset Management LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at $200,000. Bridgefront Capital LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at $204,000. Finally, Mesirow Financial Investment Management Inc. bought a new stake in ANI Pharmaceuticals in the 1st quarter valued at $206,000. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ANIP shares. HC Wainwright reaffirmed a "buy" rating and issued a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, August 11th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Guggenheim reaffirmed a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $84.75.

Insider Activity at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 50,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total transaction of $4,303,500.00. Following the transaction, the chief financial officer directly owned 180,863 shares in the company, valued at $15,566,878.41. The trade was a 21.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Chad Gassert sold 20,000 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the transaction, the senior vice president owned 173,226 shares in the company, valued at $15,065,465.22. This represents a 10.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 405,538 shares of company stock worth $35,690,131 over the last ninety days. Company insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Stock Down 0.1%

ANIP stock traded down $0.10 during midday trading on Thursday, hitting $91.78. The company's stock had a trading volume of 58,132 shares, compared to its average volume of 371,538. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $92.65. The company's fifty day moving average price is $72.27 and its 200 day moving average price is $66.56. The stock has a market capitalization of $1.99 billion, a P/E ratio of -119.19 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period in the previous year, the business earned $1.02 EPS. The company's revenue was up 53.2% compared to the same quarter last year. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.